Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 200Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

Dexamethasone 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Blood Specimen Collection 4Surveys and Questionnaires 3Prednisone 3Melphalan 3Lenalidomide 3Biopsy, Fine-Needle 3fluciclovine F-18 2carfilzomib 2Positron-Emission Tomography 2Mammography 2Injections 2Immunohistochemistry 2Gemcitabine 2Cytarabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2weifuchun 1vistusertib 1venetoclax 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1phosphoribosylformylglycinamidine synthetase 1pembrolizumab 1ofatumumab 1obinutuzumab 1lortalamine 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Disease × Lenalidomide × Clear all
NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02215980 2024-07-22

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Fondazione EMN Italy Onlus

Phase 3 Completed
210 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01160107 2023-06-29

RP_MPR

Fondazione EMN Italy Onlus

Phase 2 Completed
46 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡